According to stock exchange filings, multiple entities under Saif Partners participated in the bulk deals, selling shares worth about ₹964 crore. Saif Partners, which is among Paytm‘s earliest investors, was rebranded as Elevation Capital in 2020.

Societe Generale, Marshall Wace Investment Strategies and Morgan Stanley Asia were among the major participants in these block deals.

Over the past nearly two years, Elevation Capital and AntFin — the financial affiliate of Alibaba Group, have emerged among the biggest sellers in Paytm through block deals.

According to BSE data, around 8.5 million shares changed hands on May 22, with Saif III Mauritius selling around 5.6 million shares and the others being multiple different funds of Saif Partners.

Historical data suggest that Ant Financial has also sold 85.3 million shares across multiple tranches and bulk deals.

The Noida-headquartered company has seen several early investors liquidate their holdings. Paytm has also been encouraging Chinese investor Ant Financial to pare its stake in the firm.
Paytm closed FY26 with a net profit of ₹556 crore — its first-ever full-year profit — and reported operating revenue of ₹8,437 crore, up 22% from ₹6,900 crore a year earlier.
In April 2026, Paytm became an Indian-owned and controlled company after domestic investors raised their collective stake to around 50%. The fintech company currently trades at a market capitalisation of ₹71,220 crore ($7.4 billion).
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

The latest Market Talks covering Financial Services. Exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0535 ET – CVC Capital Partners has teamed up with Groupe Bruxelles Lambert to launch a 10.73 billion euro bid for Italian drugmaker Recordati, in a move that might prelude future deals, RBC Capital Markets’ Natalia Webster and Charles Weston say in a research note. The bidders’ strategic rationale centers on Recordati’s requirement for increased research-and-development spending as well as future mergers and acquisitions, the analysts say. Amsterdam-listed buyout group CVC is Recordati’s controlling shareholder and the bid is aimed at taking Recordati private, the analysts say. Shares in Recordati fall 0.3%, while CVC and GBL both trade 1% higher. (adria.calatayud@wsj.com)

0531 ET – CVC Capital Partners’ bid to take Italian drugmaker Recordati private alongside Groupe Bruxelles Lambert allows the Amsterdam-listed buyout group to move its stake in the company from one fund to another, Equita Sim’s Martino De Ambroggi says. The biggest shareholder in Recordati is a company ultimately controlled by CVC Fund VII called Rossini and has committed to tender to the offer its whole 46.8% stake, the analyst says. CVC participates in the takeover bid through a new fund, CVC Fund IX, and there are other minority investors such as Recordati Chairman Andrea Recordati, he adds. The CVC-GBL consortium said the offer is subject to achieving ownership of at least two-thirds of Recordati’s share capital. Shares in CVC rise 1.2%. (adria.calatayud@wsj.com)

0513 ET – Groupe Bruxelles Lambert’s investment in Italy’s Recordati to take the drugmaker private alongside CVC Capital Partners looks like a good, but risky move, ING’s David Vagman says in a research note. The Belgian investor is putting up 1.3 billion euros, which fits within its investment range of 500 million to 1.5 billion euros but is toward the higher end, the analyst says. “We find the move very interesting, showing self-confidence, but also an appetite for risks, in term of operation and leverage, which might surprise investors.” The offer also shows that GBL is keen on healthcare, a sector where it is already present in services and medical-technology, ING says. Shares in GBL rise 0.9%. (adria.calatayud@wsj.com)

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0955 ET – The American Society of Clinical Oncology published an abstract of a study that JPMorgan calls “highly encouraging” for the targeted chemotherapy sac-TMT treatment jointly developed by Merck and Chinese biotech firm Kelun-Biotech. “Sac-TMT reduced the risk of death or progression on the combined population by 65%,” the analysts say. However, they also say in the note that the drug was compared to Merck’s own Keytruda monotherapy, which is not the standard of care in most parts of the world, making drawing comparisons difficult. “The data is nonetheless solid…and continues to derisk sac-TMT,” the analysts say. Merck is up 4%.(nicholas.miller@wsj.com)

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

The logistics provider has rebranded including its three facilities in Washington

A key logistics provider to Nissan’s Washington operation has rebranded from Vantec to Logisteed UK Limited as it sets out to show “huge opportunity” in its sector.

The move brings distinctive new signage to the firm’s properties in Washington, which can be seen by motorists on the A1231 Sunderland Highway and Northbound on the A19. It marks a transition to the international Logisteed Group which operates across 122 companies, 1,003 sites and 30 countries and regions.

The name combines the word ‘logistics’ with ‘exceed, proceed, succeed and speed’, the company says. Martin Kendall, managing director, at Logisteed UK, said: “We’re delighted to now be Logisteed UK Limited.

“The change represents an important transition in the business, as we firmly establish ourselves as part of a global group that will open up exciting new opportunities for our business and for our colleagues.

“It’s incredible to think that a business that started out operating from a competitors facility as a logistics supplier to Nissan in the early days of its life here in Sunderland is now part of a global group, creating hundreds of jobs in Sunderland and across the UK, supporting blue-chip clients in automotive, premium automotive, construction, electric battery, offshore renewable energy, HVAC, commercial lighting and fashion sectors The business has come so far, and this marks a bold new chapter for us – one filled with opportunity, innovation and global ambition.”

Logisteed UK Limited operates 13 sites across the country with three of those being its own purpose-built facilities. They include a 40,500 sqm head office at Hillthorn Business Park, as well as a 38,750 sqm site at Turbine Business Park. The company also manages a 3,300 sq metre centre in Basingstoke.

The business started in early 1990 as Autrans, before becoming Vantec Europe Limited in 2007 and now Logisteed.

Mr Kendall added: “We really want to show people that there is huge opportunity in this sector, and outdated perceptions of warehouse work no longer reflect the reality of today’s logistics industry. This is an industry with so much going for it, and we’ll support colleagues to reach their full potential, whether that is through education, training or opportunities to experience work in different locations.”

He went on to say: “There was previously huge interest in the work we’ve been doing here within the Vantec Corporation, and it has already been exported to Japan. But we now have a great platform to showcase what we’re doing and the skills of the team, there’s already been interest in the technology from Logisteed’s head office in Tokyo.”